The most credible promise of artificial intelligence in medicine may be far less spectacular than the artificial doctor envisioned for years: not replacing caregivers, but preventing critical information from getting lost within a now unmanageable volume of data. This is precisely the problem tackled by Implicity, a company founded between Paris and Cambridge, Massachusetts, which has raised €35 million in a round led by IRIS alongside Five Arrows, the alternative investment arm of Rothschild & Co.
The company develops a remote cardiac patient monitoring platform that aggregates and normalizes data from implantable devices made by different manufacturers. According to the company, the system is used by over 250 medical centers and monitors more than 120,000 patients daily across the United States, France, and Germany.
The problem is not gathering data, but understanding what matters
Pacemakers, defibrillators, and other cardiac devices generate a continuous stream of information. For a healthcare facility, this availability is invaluable, but it creates a paradox: increasing the capacity to observe the patient also increases the number of signals a team must review. Redundant alerts, disparate interfaces, and non-interoperable systems can turn monitoring into an administrative burden.
Implicity attempts to build a unified layer on top of this fragmentation. AI is used to classify and prioritize events, aiming to bring what warrants intervention to clinicians' attention more quickly.
A manufacturer-independent platform
One of the strategic aspects is hardware neutrality. A hospital may have patients with devices from different companies, each tied to its own proprietary ecosystem. Aggregating those streams means sparing staff from constantly juggling separate platforms.
It is an example of how healthcare AI can generate value without inventing a new device: it can function as a coordination infrastructure connecting already installed technologies, clinical staff, and patients.
The mortality data must be read carefully
Implicity reports clinical outcomes associated with the use of its platform, including a 26 percent reduction in mortality and a 4 percent drop in hospitalizations. These are significant figures, but when covering medical technologies, it is essential to distinguish between observed associations and study results, and the promise that software will automatically produce the same outcome in any setting.
Digital medicine gains serious adoption when it can demonstrate not just algorithmic accuracy, but tangible benefits in real-world clinical workflows. It is precisely this transition—from AI that identifies patterns to AI embedded in a clinical process—that determines the technology's value.
The capital will primarily serve the United States
The new funding will be used to accelerate US commercial operations, strengthen the European presence, and invest further in predictive and diagnostic algorithms. For a medtech company, expanding into the United States means tackling a massive yet complex market where regulation, reimbursements, and integration with hospital systems matter at least as much as software quality.
Growth potential will therefore hinge on the ability to demonstrate that the platform reduces operational workloads and helps healthcare facilities monitor more patients without compromising the quality of care.
Healthcare is one of the toughest tests for AI
In many sectors, artificial intelligence is marketed as a tool to produce more content. In healthcare, the challenge is almost the opposite: there is already too much data and too little human time to interpret it. Algorithms become useful when they compress complexity, flag priorities, and leave the decision to the physician.
This is an important distinction for the broader debate on work as well. The case of Implicity suggests that some of the most compelling applications do not stem from replacing professionals, but from eliminating part of the repetitive cognitive labor that separates them from the patient.
From telemedicine to continuous medicine
Remote monitoring also transforms the very concept of a medical visit. Traditionally, medicine observes patients at discrete points in time; connected devices, by contrast, make it possible to capture signals between appointments. AI can make this continuity operationally sustainable, turning a deluge of data into an actionable list of cases requiring further review.
If this architecture works at scale, the real shift will not be having an algorithm that “plays cardiologist,” but a healthcare system capable of noticing sooner when something is changing. It is a less cinematic revolution, but likely far more useful.
